Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products
    • Neurovascular
    • Peripheral
    • Coronary
  • About us
    • Management
    • Board of Directors
    • Quality system
    • Investors
  • News & Media
    • 2018
    • 2017
    • 2016
    • 2015 and earlier
  • Contact
Qvanteq

Category: News

2018

Qvanteq AG ISO 13485 re-certified

Posted on 7. February 20187. February 2018

Qvanteq completed ISO13485 re-certification under the guidance of the notified body DEKRA.

2017

Financing round completed

Posted on 30. October 20177. February 2018

Qvanteq AG completed a financing round. It provides the company with sufficient cash to further develop its technology for vascular stents such as intracranial stents and flow diverters.

2017

Qvanteq’s technology in peer-reviewed journals

Posted on 7. April 20177. February 2018

In vivo data involving Qvanteq’s surface technology was published in the April issue of the journal Eurointervention.

2016

QUEST I FIM study completed

Posted on 25. September 20167. February 2018

Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.

2016

Qvanteq obtained government funding in the form of a new CTI/KTI project (19305.1 PFLS-LS)

Posted on 30. July 20167. February 2018

The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.  

Posts navigation

1 2 … 5 Next

Recent News

  • Qvanteq AG ISO 13485 re-certified
  • Financing round completed
  • Qvanteq’s technology in peer-reviewed journals
  • QUEST I FIM study completed
  • Qvanteq obtained government funding in the form of a new CTI/KTI project (19305.1 PFLS-LS)

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG